Dr. Paul Bernard Romesser, MD

Dr. Romesser practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Romesser's NPI, 1699074492, was assigned on March 18, 2011. Dr. Romesser graduated from Boston University School Of Medicine in 2011. Dr. Romesser's New York license number on file is 266291.

Dr. Romesser's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Romesser's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Monmouth. Dmand AI also links Dr. Romesser to 3 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Romesser practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Romesser's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Romesser is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Romesser's licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists anal cancer radiation, bone cancer radiation, brain cancer radiation, breast cancer radiation, colorectal cancer radiation, lymphoma radiation and pancreatic cancer radiation among the conditions Dr. Romesser treats.

CMS data shows 1,753 Medicare services from Dr. Romesser across 13 procedure codes in 2024, for 370 Medicare patients. Medicare paid $117,283 for them.

CMS counts 370 Medicare patients who saw Dr. Romesser in 2024. The largest group is 65 to 74, with 180 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.29, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Romesser's median patient age at 71, with 51% women.

In 2024, Dr. Romesser wrote 97 Medicare Part D claims for 35 patients. 91% of them were for generic drugs. CMS names the drug for 31 of them, across 2 drugs with 11 or more claims each, at $946 in total drug cost. In 2023, CMS named 36 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Romesser for performance year 2024, reported as part of a group. Dr. Romesser accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Romesser as offering telehealth.

Dmand AI links 91 papers to Dr. Romesser, published from 2011 to 2025. 2024 was the busiest year, with 18. The most frequent topics are Chemoradiotherapy, Rectal Neoplasms and Carcinoma, Squamous Cell. Dr. Romesser has published most often in Int J Radiat Oncol Biol Phys. Dr. Romesser's most frequent co-authors are Christopher H. Crane, MD, Jesse Joshua Smith, MD, PhD and Philip B. Paty, MD.

Dmand AI links Dr. Romesser to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Rectal Diseases and Carcinoma, Bronchogenic. Memorial Sloan Kettering Cancer Center sponsors the most, 2.

CMS Open Payments shows 24 general payments to Dr. Romesser from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 94% of the total. EMD Serono, Inc. paid the most, $31,321.

Dmand AI lists 1 award for Dr. Romesser, most recently AOA Inductee 2011 in 2011.

Dr. Romesser graduated from Boston University School Of Medicine in 2011. Dr. Romesser is a member of AOA.

Dr. Romesser is in network with 13 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.